Murphy Pohlad Asset Management LLC Purchases 12,140 Shares of Abbott Laboratories $ABT

Murphy Pohlad Asset Management LLC boosted its position in Abbott Laboratories (NYSE:ABT - Free Report) by 398.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,186 shares of the healthcare product maker's stock after buying an additional 12,140 shares during the quarter. Murphy Pohlad Asset Management LLC's holdings in Abbott Laboratories were worth $1,378,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC grew its position in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after purchasing an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC lifted its position in shares of Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock worth $648,000 after purchasing an additional 162 shares during the last quarter. United Bank boosted its stake in Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock valued at $3,945,000 after purchasing an additional 2,001 shares during the period. Main Street Financial Solutions LLC boosted its stake in Abbott Laboratories by 13.6% during the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker's stock valued at $1,618,000 after purchasing an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board grew its holdings in Abbott Laboratories by 25.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker's stock valued at $195,267,000 after buying an additional 292,547 shares during the last quarter. Institutional investors own 75.18% of the company's stock.

Abbott Laboratories Stock Up 1.6%

Shares of ABT opened at $114.50 on Thursday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The company has a 50-day moving average price of $99.02 and a two-hundred day moving average price of $99.90. The stock has a market cap of $198.13 billion, a price-to-earnings ratio of 37.06, a P/E/G ratio of 2.18 and a beta of 0.59. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same period in the prior year, the company posted $1.26 EPS. The company's revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.2%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories's dividend payout ratio is currently 81.55%.

Analysts Set New Price Targets

A number of brokerages have recently commented on ABT. Bank of America cut their price target on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. UBS Group lowered their price objective on shares of Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday, July 28th. Royal Bank Of Canada reiterated an "outperform" rating and set a $130.00 target price on shares of Abbott Laboratories in a research note on Friday, July 17th. Wolfe Research raised shares of Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price target for the company in a report on Thursday, August 13th. Finally, BTIG Research raised their price target on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a "buy" rating in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and a consensus target price of $118.67.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source